Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC. (Q53581146)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24705479%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

title

Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24705479%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

1 reference

acute myeloid leukemia

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24705479%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Andrew W. Roberts

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24705479%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Angel F. Lopez

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24705479%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Louis Fabri

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24705479%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Richard B Lock

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24705479%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

author name string

S J Busfield

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24705479%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

M Biondo

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24705479%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

M Wong

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24705479%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

E M Lee

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24705479%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

S Ghosh

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24705479%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

H Braley

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24705479%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

C Panousis

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24705479%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

S Z He

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24705479%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

D Thomas

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24705479%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

G Vairo

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24705479%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

A D Nash

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24705479%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

publication date

7 April 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24705479%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24705479%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24705479%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24705479%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

page(s)

2213-2221

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24705479%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/leu.2014.128

13 March 2020

exact match

0 references

cites work

Current treatment of acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.128

Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.128

A cell initiating human acute myeloid leukaemia after transplantation into SCID mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.128

Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.128

Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.128

Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.128

Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.128

Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.128

Overexpression of CD123 correlates with the hyperdiploid genotype in acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.128

The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.128

Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.128

Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.128

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.128

Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.128

Engineered antibody Fc variants with enhanced effector function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.128

Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.128

Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.128

Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.128

Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.128

A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.128

CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.128

CD56dimCD16neg cells are responsible for natural cytotoxicity against tumor targets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.128

In vitro improvement of a shark IgNAR antibody by Qbeta replicase mutation and ribosome display mimics in vivo affinity maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.128

Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.128

Is it time to revisit standard post-remission therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.128

Recent advances in acute myeloid leukemia stem cell biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.128

Expression of interleukin-3 receptor subunits on defined subpopulations of acute myeloid leukemia blasts predicts the cytotoxicity of diphtheria toxin interleukin-3 fusion protein against malignant progenitors that engraft in immunodeficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.128

Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.128

Engineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.128

Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.128

Natural killer cell immune escape in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.128

Activation, coactivation, and costimulation of resting human natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.128

Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.128

Retraction. Roman-Gomez J, Cordeu L, Agirre X, Jimenez-Velasco A, San Jose-Eneriz E, Garate L, Calasanz MJ, Heiniger A, Torres A, Prosper F. Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia. Blood. 2007;109(8):3462-3469

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.128

"Superhumanized" antibodies: reduction of immunogenic potential by complementarity-determining region grafting with human germline sequences: application to an anti-CD28

21 January 2018

1 reference

12 December 2020

Target-induced natural killer cell loss as a measure of NK cell responses

1 reference

12 December 2020

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene

1 reference

12 December 2020

Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia

1 reference

12 December 2020

The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates

1 reference

12 December 2020

Distinct expression patterns of CD123 and CD34 on normal bone marrow B-cell precursors ("hematogones") and B lymphoblastic leukemia blasts

1 reference

12 December 2020

Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies

1 reference

12 December 2020

Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype

1 reference

12 December 2020

Monoclonal antibody 7G3 recognizes the N-terminal domain of the human interleukin-3 (IL-3) receptor alpha-chain and functions as a specific IL-3 receptor antagonist

1 reference

12 December 2020

A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting

1 reference

12 December 2020

Growth factor receptor profile of CD34+ cells in AML and B-lineage ALL and in their normal bone marrow counterparts

1 reference

12 December 2020

Pre-eminence and persistence of immature natural killer cells in acute myeloid leukemia patients in first complete remission

1 reference

12 December 2020

Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia

1 reference

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1182/BLOOD-2006-09-047043

Identifiers

DOI

10.1038/LEU.2014.128

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24705479%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

1 reference